Search Within

Steven Maron

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (6)
Groups
  1. Body Imaging Service (13)
  2. Department of Medicine (13)
  3. Gastrointestinal Oncology Service (13)
  4. Radiology, Department of (13)
  5. Solid Tumor Oncology Division (13)
  6. Center for Pancreatic Cancer Research (12)

More Groups

People
  1. Yelena Janjigian (12)
  2. Geoffrey Ku (10)
  3. Joanne Chou (10)
  4. Marinela Capanu (10)
  5. Viktoriya Paroder (9)
  6. David Ilson (8)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (2)
  4. 2021 (2)
  5. 2020 (2)
  6. 2019 (2)
Publications
  1. Journal of Clinical Oncology (5)
  2. Annals of Oncology (2)
  3. Journal of Nuclear Medicine (2)
  4. Lancet Oncology (2)
  5. Annals of Surgical Oncology (1)
  6. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. Elsevier Science, Inc. (2)
  3. Oxford University Press (2)
  4. Society of Nuclear Medicine (2)
  5. American Association for Cancer Research (1)
  6. Springer (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using (18)F-BMS-986229 PET
    Meeting Abstract

    Cytryn, S. L.; Pandit-Taskar, N.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Feder, L.; Philemond, S.; Lyashchenko, S. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • (18)F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer
    Journal Article

    Cytryn, S. L.; Pandit-Taskar, N.; Lumish, M. A.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Antoine, A.; Loegel, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: A pilot study
    Journal Article

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Chou, J. F.; Capanu, M.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Lyashchenko, S. K.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Local therapy for oligoprogression or consolidation in high mutational burden stage 4 colorectal cancer treated with PD-1 or PD-L1 blockade
    Journal Article

    Klemen, N. D.; Court, C. M.; Fernandes, M. C.; Walch, H. S.; Chatila, W. K.; Saadat, L. V.; Maron, S.; Crane, C.; Shia, J.; Cercek, A.; more...
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Imaging HER2-positive metastatic esophagogastric cancer with (89)Zr-trastuzumab PET and (18)F-FDG PET
    Meeting Abstract

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Janjigian, Y. Y.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save